<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04049630</url>
  </required_header>
  <id_info>
    <org_study_id>EOLoa/LEV</org_study_id>
    <nct_id>NCT04049630</nct_id>
  </id_info>
  <brief_title>Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients</brief_title>
  <acronym>EOLoa</acronym>
  <official_title>Randomized Clinical Trial, Double-blind, Dose-escalating of Drug Intensities, Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Programme National de Lutte contre l'Onchocercose, Republic of the Congo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Programme National de Lutte contre l'Onchocercose, Republic of the Congo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at evaluating the safety and efficacy of levamisole in patients with loiasis&#xD;
      infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial will be conducted in Republic of Congo. This is a pragmatic and&#xD;
      adaptative randomized, double-blind clinical trial. Levamisole will be tested at 1 and 1,5&#xD;
      mg/kg, and compared to placebo (36:36:36); or 2,5 mg/kg compared to placebo (36:36) in case&#xD;
      of adaptation of the dose for cohorts II and III.&#xD;
&#xD;
      We will perform three cohorts of patients according to the microfilarial density : 1-1,999&#xD;
      mf/ml, 1-14,999 mf/ml, and all microfilaremic individuals; in order to respect the safety&#xD;
      potentially related to loiasis.&#xD;
&#xD;
      The first cohort was to evaluate the most appropriate dose of levamisole, with a possibility&#xD;
      to increase (to 2.5 mg/kg) the dose of levamisole for the cohorts II and III in case of lack&#xD;
      of efficacy and in case of good safety profil.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 16, 2021</start_date>
  <completion_date type="Actual">July 15, 2021</completion_date>
  <primary_completion_date type="Actual">April 24, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of levamisole</measure>
    <time_frame>1 week</time_frame>
    <description>Absence of severe adverse events during the first week</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events with levamisole</measure>
    <time_frame>1 week</time_frame>
    <description>Proportion of adverse events during the first week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of levamisole</measure>
    <time_frame>Day 2, Day 7, and Month 1</time_frame>
    <description>Proportion of reduction of the microfilarial density of Loa loa at Day 2, Day 7, and Month 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of individuals without microfilariae of Loa loa</measure>
    <time_frame>Day 7 and 1 Month</time_frame>
    <description>Proportion of individuals with a diminution of 40% and 80% and more of the microfilarial density at Day 7 and Month 1</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">255</enrollment>
  <condition>Onchocerciasis, Ocular</condition>
  <condition>Loiasis</condition>
  <arm_group>
    <arm_group_label>LEV 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets of LEV at 1 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEV 1,5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet of LEV at 1,5 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEV 2,5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet of LEV at 2,5 mg/kg will be administrated to the participant ; in single dose only one time. The number of tablets of LEV of 50 mg or 10 mg will be adapted according to the weight of the participant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablets of placebo will be administrated to the participant in single dose only one time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEV 1 mg/kg</intervention_name>
    <description>A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.</description>
    <arm_group_label>LEV 1 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEV 1,5 mg/kg</intervention_name>
    <description>A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.</description>
    <arm_group_label>LEV 1,5 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEV 2,5 mg/kg</intervention_name>
    <description>A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.</description>
    <arm_group_label>LEV 2,5 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5 tablets of placebo will be administrated to the participants.</description>
    <arm_group_label>LEV 1 mg/kg</arm_group_label>
    <arm_group_label>LEV 1,5 mg/kg</arm_group_label>
    <arm_group_label>LEV 2,5 mg/kg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written consent written, signed (or with thumbprint) and dated&#xD;
&#xD;
          -  Aged 18 to 65 inclusive&#xD;
&#xD;
          -  Individual microfilarial density ≥ 1mf/mL&#xD;
&#xD;
          -  Body weight ≥ 40 kg in women and ≥ 45 kg in men; and less than 85 kg&#xD;
&#xD;
          -  In good health condition, as determined by the medical questionnaire and the general&#xD;
             clinical examination: absence of acute or chronic infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in any study other than purely observational, in the 4 weeks preceding&#xD;
             this study (determined by the theoretical date of administration of LEV or placebo).&#xD;
&#xD;
          -  Any vaccination in the 4 weeks preceding this study.&#xD;
&#xD;
          -  Acute infection requiring a treatment in the 10 days preceding this study, determined&#xD;
             by the anamnesis during the medical interview (example: pulmonary infection, ENT,&#xD;
             digestive, cutaneous, with implementation of an antibiotic treatment or not)&#xD;
&#xD;
          -  Warfarin treatment&#xD;
&#xD;
          -  Treatment with clozapine, phenythiazines, sulfasalazine, carbamazepine, synthetic&#xD;
             antithyroid, ticlopidine, cimetidine, and gold salts: whether it is a long-term&#xD;
             treatment, or a treatment given in a single dose 10 days before the start of treatment&#xD;
             for the clinical trial (precaution of use compared to the risk of agranulocytosis of&#xD;
             immuno-allergic or toxic origin)&#xD;
&#xD;
          -  Known immunosuppressive pathology&#xD;
&#xD;
          -  Past or current history of neurological (including epilepsy) or neuropsychiatric&#xD;
             disease&#xD;
&#xD;
          -  History of agranulocytosis&#xD;
&#xD;
          -  Consumption of alcohol, taking cocaine or other drugs of abuse in the 72 hours&#xD;
             preceding the administration of the treatment of the test determined by the anamnesis&#xD;
             during the medical interview&#xD;
&#xD;
          -  Any condition, in the opinion of the investigator, which exposes the subject to an&#xD;
             undue risk&#xD;
&#xD;
          -  Known intolerance to levamisole&#xD;
&#xD;
          -  Subjects who gave blood in the 8 weeks before entry into the study, with a standard&#xD;
             volume (&gt; 500 mL)&#xD;
&#xD;
          -  During the clinical examination: symptoms, physical signs or biological constants&#xD;
             suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary,&#xD;
             cutaneous, immunodeficiency, psychiatric disorders and other abnormalities likely to&#xD;
             interfere with the interpretation results of the test. The doctor may then give a&#xD;
             favorable or unfavorable opinion for the inclusion of the participant&#xD;
&#xD;
          -  Taking IVM and / or LEV during the last six months; and / or mebendazole or&#xD;
             albendazole in the last month&#xD;
&#xD;
          -  Pregnant and lactating women (based on self-declaration)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Secteur opérationnelle de la Santé, Ministère de la Santé et de la Population</name>
      <address>
        <city>Sibiti</city>
        <country>Congo</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Congo</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onchocerciasis</mesh_term>
    <mesh_term>Onchocerciasis, Ocular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

